Pfizer’s COVID-19 booster vaccine, pneumococcal jab examined in older adults

The primary contributors aged 65 and older have obtained vaccinations in a brand new research assessing coadministration of a pneumococcal jab together with a COVID-19 booster shot, Pfizer introduced on Monday. Trial investigators are aiming to check the protection and ensuing immune response, following contributors as much as six months post-vaccination.

The trial includes 600 adults recruited from the corporate’s prior late-stage COVID-19 vaccine trial. Members should obtain each COVID-19 vaccines at the very least six months earlier than becoming a member of the brand new research, Pfizer stated in a assertion. Members have been randomly assigned to one of many following teams:

  • Pneumococcal vaccine and a 3rd dose of Pfizer’s COVID-19 vaccine
  • Pneumococcal vaccine and a placebo
  • Third dose of Pfizer’s COVID-19 vaccine and a placebo


In vaccine makers’ late-stage scientific trials, contributors have been prohibited from getting vaccines 14 days earlier than to 14 days after receiving their COVID-19 vaccine, Dr. Greg Poland, professor of medication and infectious ailments on the Mayo Clinic and director of the Mayo Vaccine Analysis Group, instructed Fox Information.

“Now that we’ve real-world effectiveness research, the problem has been, that’s very disruptive given how many individuals, due to the pandemic, are behind on their immunization standing, significantly children and older adults,” Poland defined. “So these are research are designed to have a look at the protection and any interference with the efficacy of the COVID vaccine once you coadminister it, in different phrases in a single arm you get the COVID vaccine, within the different arm you get your pneumococcal vaccine.”


Poland says coadministration is outlined as at the very least 1 inch aside, although investigators sometimes favor to coadminister vaccines in numerous limbs to keep away from complicated any native reactions. Typically vaccine recipients develop a pores and skin rash following vaccination, so coadministration in a single arm might make it troublesome to tell apart between potential reactions.

Pfizer did not instantly return a request for remark.

Based on the Division of Well being and Human Providers, pneumococcal illness is attributable to a standard kind of germ, unfold by means of coughs or sneezes. Ensuing sickness is normally gentle however may cause bigger points like ear, lung, blood or mind infections. Whereas everybody wants pneumococcal vaccines, it’s particularly vital for infants, adults over 65 and other people with weakened immune programs and underlying well being situations, HHS says. Potential uncomfortable side effects post-vaccination embody a sore arm or fever, normally resolving in a number of days.

One thought on “Pfizer’s COVID-19 booster vaccine, pneumococcal jab examined in older adults

  1. Great information. Lucky me I found your website by chance (stumbleupon). I have book-marked it for later!

Leave a Reply

Your email address will not be published. Required fields are marked *